Woodline Partners LP Vaxcyte, Inc. Transaction History
Woodline Partners LP
- $17.6 Billion
- Q2 2025
A detailed history of Woodline Partners LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 200,078 shares of PCVX stock, worth $9.06 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
200,078
Previous 1,111,777
82.0%
Holding current value
$9.06 Million
Previous $42 Million
84.51%
% of portfolio
0.04%
Previous 0.29%
Shares
16 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$665 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$543 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$542 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$450 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$272 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.69B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...